Across TCGA pan-cancer cohorts, SBK2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SBK2 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SBK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SBK2 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

BLCA, PAAD, and LGG are the cancer types where SBK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	36	view →
PAAD	OS	Median	All	0.131	0.613	.001	15	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.192	0.707	.046	3	view →
SCLC	OS	Median	III,IV	1.000	0.404	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SBK2 tumor-vs-normal RNA expression · all SBK2 data types